How has been the historical performance of Mankind Pharma?
Mankind Pharma has shown consistent growth in net sales and profits over the past five years, with net sales increasing from INR 6,214.43 crore in March 2021 to INR 12,207.44 crore in March 2025, and profit after tax rising from INR 1,281.35 crore to INR 1,994.35 crore in the same period. The earnings per share improved from INR 28.08 to INR 48.25, reflecting strong financial performance.
Answer:The historical performance of Mankind Pharma shows a consistent growth trajectory in net sales and profits over the past five years.Breakdown:
Mankind Pharma's net sales have increased significantly from INR 6,214.43 crore in March 2021 to INR 12,207.44 crore in March 2025, reflecting a strong upward trend. The total operating income followed a similar pattern, rising from INR 6,214.43 crore in March 2021 to INR 12,207.44 crore in March 2025. The total expenditure, excluding depreciation, also grew from INR 4,566.33 crore in March 2021 to INR 9,189.51 crore in March 2025, indicating increased operational costs alongside revenue growth. Operating profit (PBDIT) has shown a robust increase, reaching INR 3,554.72 crore in March 2025, up from INR 1,819.05 crore in March 2021. Profit before tax has also risen, reaching INR 2,504.09 crore in March 2025, compared to INR 1,679.93 crore in March 2021. The profit after tax saw a similar increase, growing from INR 1,281.35 crore in March 2021 to INR 1,994.35 crore in March 2025. The earnings per share (EPS) improved from INR 28.08 in March 2021 to INR 48.25 in March 2025, showcasing enhanced shareholder value. Overall, Mankind Pharma has demonstrated strong financial performance with increasing revenues, profits, and EPS over the years.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
